ArticleCancer management and research2026
Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nutritional status is a recognized prognostic factor in oncology. However, its impact on patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) treated with the PD-L1 inhibitor KL-A167 remains unclear. Methods: We conducted a secondary exploratory analysis of the KL-A167 trial, which included 153 patients with R/M NPC who had progressed after at least two lines of chemotherapy. Baseline nutritional status was assessed using the Controlling Nutritional Status (CONUT) score, Nutritional Risk Index (NRI), and Prognostic Nutritional Index (PNI). The associations between these indices and survival outcomes, including overall survival (OS) and progression-free survival (PFS), were analyzed using Kaplan-Meier methods and Cox regression models. Results: Baseline nutritional status was associated with survival outcomes. In multivariable Cox analyses as continuous variables, higher CONUT, lower NRI, and lower PNI were all independently associated with worse OS (all Conclusion: Baseline nutritional indices, particularly PNI, were associated with OS and PFS in patients with R/M NPC treated with the PD-L1 inhibitor KL-A167. Routine baseline nutritional screening may help identify high-risk patients before immunotherapy, although the clinical benefits of early nutritional interventions remain to be confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.